When was Biopharma Excellence founded?

Biopharma Excellence was founded in 2013.

Where is Biopharma Excellence located?

Biopharma Excellence is headquartered in Germany.

How many employees does Biopharma Excellence have?

As of Dec 31, 2020, the latest employee count at Biopharma Excellence is 271.

Is Biopharma Excellence a funded company?

Biopharma Excellence is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does Biopharma Excellence rank among its competitors?

Biopharma Excellence ranks 43rd amongst 97 active competitors, of which 21 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Pluri, which secured $2.5M in Mar, 2026.

Who are the top competitors of Biopharma Excellence?

Biopharma Excellence's top competitors include Pluri, Mytos and Oxford BioMedica. Among them, Pluri secured the most recent funding round in March, 2026.

Biopharma Excellence - 2026 Company Profile & Competitors

Biopharma Excellence is an unfunded company based in Germany, founded in 2013. It operates as a Provider of biopharmaceutical product development, regulatory, and clinical trial support. Biopharma Excellence has not raised any funding yet. The company has 97 active competitors, including 21 funded and 16 that have exited. Its top competitors include companies like Pluri, Mytos and Oxford BioMedica.

Company Details

Provider of biopharmaceutical product development, regulatory, and clinical trial support. The company offers assistance with product strategy, global regulatory navigation, and integrated product development. It also provides services such as non-clinical and quality assessments, clinical program execution, and marketing authorization support. The company supports various product types, including vaccines, and offers due diligence and partnering assistance.

Key Metrics

Founded Year

2013

Location

Germany

Stage

Unfunded

Ranked

43^rd among 97 active competitors

Employee Count

271 as on Dec 31, 2020

Similar Companies

Pluri & 105 more

View Biopharma Excellence's full profile

Biopharma Excellence is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
PharmaLex GmbH CIN: HRB13017 , Germany, Active	Aug 25, 2014	-	271 (As on Dec 31, 2020)

Biopharma Excellence has not raised any funding rounds yet.

Biopharma Excellence's employee count trend

Biopharma Excellence has 271 employees as of Dec 20. The total employee count is 8.0% lower than what it was in Dec 19. Here is Biopharma Excellence's employee count trend over the years:

Employee count trend for Biopharma Excellence

Uncover Biopharma Excellence's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Biopharma Excellence include Pluri, Mytos and Oxford BioMedica. Here is the list of Top 10 competitors of Biopharma Excellence, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Pluri 2003, Haifa (Israel), Public	Developer of three-dimensional cell expansion platforms for various industries	-	Merchant Adventure Investment Advisors, Europa ... & 2 others	60/100
2nd	Mytos 2016, London (United Kingdom), Series A	Provider of automated cell manufacturing for regenerative medicine applications	$19M	Buckley Ventures, Artis Ventures & 6 others	58/100
3rd	Oxford BioMedica 1995, Oxford (United Kingdom), Public	Gene and cell therapy group specializing in the development and manufacturing of viral vector-based medicines.	-	Vitruvian Partners, WG Partners & 6 others	58/100
4th	Orgenesis 2008, Germantown (United States), Public	Developer of cell and gene therapies for multiple disorders	-	Kodiak Capital, Metalmark Capital & 4 others	55/100
5th	Porton Advanced Solutions 2018, Suzhou (China), Series B	Provider of cell & gene therapy, discovery research, analytical development, and testing services	$80M	China Merchants Capital, HM Capital & 6 others	49/100
6th	Genflow Biosciences 2020, Charleroi (Belgium), Public	CDMO focused on developing of gene therapies to reverse the aging processes	-	Wallonia, Longevitytech.fund & 1 others	49/100
7th	eXmoor 2004, Bristol (United Kingdom), Series A	Provider of cell & gene therapautic services for biopharmaceutical sector	$51.7M	MVM, Kineticos	48/100
8th	SpliSense 2016, Jerusalem (Israel), Series B	Limited information available	$28.5M	Orbimed, Cystic Fibrosis Foundation & 2 others	46/100
9th	Advent BioServices 2016, Sawston (United Kingdom), Acquired	CDMO focused on manufacturing of cell based therapy products	-	-	46/100
10th	Ubrigene 2015, Beijing (China), Series C	CDMO focused on providing services for cell therapy and AAV vector products	-	Cowin Capital, Goldstone Investment & 12 others	44/100
43rd	Biopharma Excellence 2013, Germany, Unfunded	Provider of biopharmaceutical product development, regulatory, and clinical trial support	-	-	27/100